Details of the Drug
General Information of Drug (ID: DM4X0WY)
Drug Name |
N-Omega-Propyl-L-Arginine
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-OMEGA-PROPYL-L-ARGININE; 137361-05-8; omega-propyl-l-arginine; CHEMBL107528; (S)-2-Amino-5-(3-propylguanidino)pentanoic acid; Nomega-Propyl-L-arginine hydrochloride; (2S)-2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; Nomega-Propyl-L-arginine; hDDAH inhibitor, 2b; Tocris-1200; NCGC00025034-01; Nomegapropyl-L-arginine; N- -Propyl-L-Arginine; 3AR; 2-amino-5-[(N'-propylcarbamimidoyl)amino]pentanoic acid; AC1L9KK0; N.omega.-propyl-L-Arginine; GTPL6525; SCHEMBL1004634; CTK8E7922; DTXSID30332245; MolPort-006-395-775
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 216.28 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | -3.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References